StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Crinetics Pharmaceuticals, Inc. by Year

Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Crinetics Pharmaceuticals, Inc.: $332M in FY2025, up 38.3% from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
332
Period ended Dec 31, 2025
Change on a year earlier
+38.3%
240 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: SEC Filing ↗

Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals, Inc., FY2018–FY2026Q2).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCrinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) ($M)Year on yearSource
FY2025Dec 31, 2025332+38.3%SEC Filing ↗
FY2024Dec 31, 2024240+42.5%SEC Filing ↗
FY2023Dec 31, 2023169+29.4%SEC Filing ↗
FY2022Dec 31, 2022130+54.6%SEC Filing ↗
FY2021Dec 31, 202184.3+47.8%SEC Filing ↗
FY2020Dec 31, 202057+37.3%SEC Filing ↗
FY2019Dec 31, 201941.5+69.6%SEC Filing ↗
FY2018Dec 31, 201824.5–SEC Filing ↗

Breakdown

What makes up crinetics Pharmaceuticals, Inc.

Cite this data

StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals, Inc. ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-rd-exp

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.